NCT07659782
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07659782
Title A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
Acronym TARGET-D 202
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Verastem, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
START LA RECRUITING Los Angeles California 90025 United States Details
Cedars-Sinai Medical Center RECRUITING Los Angeles California 90048 United States Details
Valkyrie Clinical Trials RECRUITING Los Angeles California 90067 United States Details
Emory Winship Cancer Institute RECRUITING Atlanta Georgia 30322 United States Details
START New Jersey RECRUITING East Brunswick New Jersey 08816 United States Details
NYU RECRUITING New York New York 10016 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
START Fort Worth RECRUITING Fort Worth Texas 76104 United States Details
MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
University of Virginia RECRUITING Charlottesville Virginia 22908 United States Details
Chris O'Brien Lifehouse RECRUITING Camperdown New South Wales 2050 Australia Details
Macquarie University Hospital RECRUITING Sydney New South Wales 2109 Australia Details
ICON Cancer Centre South Brisbane RECRUITING Brisbane Queensland 4101 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field